Catalyst Pharmaceuticals Director Sells $525K of Stock Amid 19.44% Revenue Growth

David S Tierney, Director at Catalyst Pharmaceuticals CPRX, sold 26,000 shares for $525,200 on August 28. The company's shares are trading at $20.49, up 0.54%. Catalyst Pharmaceuticals achieved a 19.44% revenue growth rate in Q2 2025, with a gross margin of 85.94% and EPS of 0.43. The company's debt-to-equity ratio is 0.0, and its P/E, P/S, and EV/EBITDA ratios indicate undervaluation. Market capitalization is above industry average, emphasizing the company's significant scale and robust market position.

Coral Gables, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (CPRX) reported robust financial results for the second quarter of 2025, showcasing a 19.4% revenue growth rate compared to the same period last year. The company achieved a gross margin of 85.94% and an earnings per share (EPS) of 0.43. Notably, David S. Tierney, Director at Catalyst Pharmaceuticals, sold 26,000 shares on August 28, 2025, for a total of $525,200, with the company's shares trading at $20.49, up 0.54% [1].

Catalyst Pharmaceuticals' strong performance in Q2 2025 was driven by its core product, FIRDAPSE® (amifampridine), which accounted for 62% of the company's net product sales in 2024. The drug, approved for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and pediatric patients, continues to be a significant revenue driver. The company's other marketed products, Fycompa (perampanel) and Agamree (vamorolone), also contributed to the overall revenue growth, providing incremental sales [2].

The company's debt-to-equity ratio stands at 0.0, indicating a strong financial position. Additionally, the company's P/E, P/S, and EV/EBITDA ratios suggest undervaluation, making it an attractive investment opportunity. Catalyst Pharmaceuticals' market capitalization is above the industry average, reflecting its significant scale and robust market position [3].

Catalyst Pharmaceuticals recently announced a settlement agreement with Lupin Pharmaceuticals regarding the FIRDAPSE patent litigation. As part of the settlement, Lupin agreed not to market its generic version of FIRDAPSE in the United States before February 2035, unless specific exceptions arise. This agreement protects Catalyst Pharmaceuticals' FIRDAPSE sales from generic erosion in the U.S. market for LEMS treatment [4].

The company is scheduled to participate in the upcoming BofA Securities Health Care Conference and the Barclays 27th Annual Global Healthcare Conference, providing investors with further insights into its growth strategies and financial outlook [5].

References:
[1] Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025. GlobeNewsWire. Retrieved from [https://stockanalysis.com/stocks/cprx/](https://stockanalysis.com/stocks/cprx/)
[2] Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals. GlobeNewsWire. Retrieved from [https://www.nasdaq.com/articles/catalyst-pharmaceuticals-settles-firdapse-patent-litigation-lupin](https://www.nasdaq.com/articles/catalyst-pharmaceuticals-settles-firdapse-patent-litigation-lupin)
[3] Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript. Seeking Alpha. Retrieved from [https://seekingalpha.com/earnings/nasdaq-cprx-2025-q2-earnings-call-transcript](https://seekingalpha.com/earnings/nasdaq-cprx-2025-q2-earnings-call-transcript)
[4] Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update. GlobeNewsWire. Retrieved from [https://globenewswire.com/news-release/2025/08/07/2131547/EN/Catalyst-Pharmaceuticals-Inc-CPRX-Reports-Record-Second-Quarter-and-First-Half-2025-Financial-Results-Provides-Business-Update.html](https://globenewswire.com/news-release/2025/08/07/2131547/EN/Catalyst-Pharmaceuticals-Inc-CPRX-Reports-Record-Second-Quarter-and-First-Half-2025-Financial-Results-Provides-Business-Update.html)
[5] Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025. GlobeNewsWire. Retrieved from [https://globenewswire.com/news-release/2025/04/30/2124572/EN/Catalyst-Pharmaceuticals-Inc-to-Participate-in-the-BofA-Securities-Health-Care-Conference-2025.html](https://globenewswire.com/news-release/2025/04/30/2124572/EN/Catalyst-Pharmaceuticals-Inc-to-Participate-in-the-BofA-Securities-Health-Care-Conference-2025.html)